AG
AMLX icon

Algert Global’s Amylyx Pharmaceuticals AMLX Stock Holding History

Algert Global’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-57,133
Closed -$202K – 1179
2025
Q1 		$202K Buy
+57,133
New +$203K 0.01% 1083
2024
Q4 		– Sell
-106,219
Closed -$344K – 1167
2024
Q3 		$344K Buy
106,219
+81,405
+328% +$183K 0.01% 972
2024
Q2 		$47K Buy
+24,814
New +$48.1K ﹤0.01% 1442
2024
Q1 		– Sell
-147,020
Closed -$2.16M – 1071
2023
Q4 		$2.16M Sell
147,020
-14,385
-9% -$220K 0.09% 387
2023
Q3 		$2.96M Buy
+161,405
New +$3.41M 0.14% 241

Other funds holding AMLX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Algert Global's AMLX Position: Q2 2025 in Review

Algert Global sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2025, closing a stake of 57,133 shares — an estimated $202K sold.

Algert Global first reported a position in AMLX in Q3 2023 and held it in 5 quarters. The position peaked at $2.96M in Q3 2023. 131 funds tracked by Wall St. Rank hold AMLX as of Q2 2025.

  • Algert Global reported no remaining Amylyx Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Algert Global sold 57,133 Amylyx Pharmaceuticals shares in Q2 2025, an estimated $202K.
  • Algert Global first reported a position in Amylyx Pharmaceuticals in Q3 2023 and held it in 5 quarters.
  • Algert Global's Amylyx Pharmaceuticals position peaked at $2.96M in Q3 2023.
  • 131 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2025.

Based on Algert Global's 13F filing for Q2 2025, filed 14 Aug 2025.